Research programme: neurological disorders therapies - Lexicon Pharmaceuticals/Bristol-Myers Squibb

Drug Profile

Research programme: neurological disorders therapies - Lexicon Pharmaceuticals/Bristol-Myers Squibb

Alternative Names: LG 262; LG 317; LG 324; LG 351; LG 451; LG 470; LG 487; LG 527; LG 590; LG 726; LG 752; LG 852; LG 915

Latest Information Update: 17 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; Lexicon Genetics
  • Developer Bristol-Myers Squibb; Lexicon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neurological disorders; Neuropathic pain

Most Recent Events

  • 01 Aug 2017 Lexicon Pharmaceuticals plans a phase I study for LX 9211 for Neuropathic pain in USA in the second half of 2017
  • 15 Apr 2015 Preclinical development is ongoing in USA
  • 21 Jan 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top